Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma

Libin Zhou1,2 | Hualong Fang3 | Fei Guo4 | Min Yin2 | Huimin Long2 | Guobin Weng5,6

1Department of Urology, The affiliated Lihuili Hospital, Ningbo University, Ningbo, China
2Department of Urology, Ningbo Medical Centre Lihuili Hospital, Ningbo, China
3The First Affiliated Hospital of Nanchang, Nanchang, China
4Ningbo Medical Centre Lihuili Hospital/ Ningbo Institute for Medicine & Biomedical Engineering Combined Innovation, Ningbo, China
5Department of Urology, The affiliated Yinzhou No 2 Hospital, Ningbo University, Ningbo, China
6Department of Urology, Ningbo Yinzhou No.2 Hospital, Ningbo, China

Correspondence
Guobin Weng, Department of Urology, Ningbo Yinzhou No 2 Hospital, Ningbo University, 998 Qianhebelu Road, Yinzhou District, Ningbo City, Zhejiang Province 315192, China. Email: ddwgw@aliyun.com

Funding information
The present study was supported by the Natural Science Foundation of Ningbo Municipality (2019A610256, 202003N4255, 20211281) and the Medicine and Health Project of Zhejiang Province (2019KY603, 2020KY858).

Abstract

Background: The tumor microenvironment (TME) is closely related to clear cell renal cell carcinoma (ccRCC) prognosis, and immunotherapy response. In current study, comprehensive bio-informative analysis was adopted to construct a TME-related lncRNA signature for immune checkpoint inhibitors (ICIs) and targeted drug responses in ccRCC patients.

Methods: The TME mRNAs were screened following the immune and stromal scores with the data from GSE15641, GSE29609, GSE36895, GSE46699, GSE53757, and The Cancer Genome Atlas (TCGA)-kidney renal clear cell carcinoma (KIRC). And the TME-related lncRNAs were recognized using correlation analysis. The TME-related lncRNAs prognostic model was constructed using the training dataset. Kaplan–Meier analysis, principal-component analysis, and time-dependent receiver operating characteristic were used to evaluate the risk model. The immune cell infiltration in TME was evaluated using the single-sample gene set enrichment analysis (ssGSEA), ESTIMATE, and microenvironment cell populations counter algorithm. The immunophenoscore (IPS) was used to assess the response to immunotherapy with the constructed model.

Results: In the current study, 364 TME-related lncRNAs were selected based on the integrated bioinformatical analysis. Six TME-related lncRNAs (LINC00460, LINC01094, AC008870.2, AC068792.1, and AC007637.1) were identified as the prognostic signature in the training dataset and subsequently verified in the testing and entire datasets. Patients in the high-risk group exhibited poor overall survival and disease-free survival than those in the low-risk group. The 1-, 3-, and 5-year areas under the curves of the prognostic signature in the entire dataset were 0.704, 0.683, and 0.750, respectively. The risk score independently predicted ccRCC survival based on univariate and multivariate Cox regression. GSEA analysis suggested that the high-risk group

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
was concentrated on immune-related pathways. The high-risk group were characterized by high immune cell infiltration, high TMB and somatic mutation counters, high IPS-PD-1+ CTLA4 scores, and immune checkpoints expression upregulation, reflecting the higher ICIs response. The half inhibitory concentrations of sunitinib, temsirolimus, and rapamycin were low in the high-risk group. 

**Conclusion:** The TME-related lncRNAs signature constructed could reliably predict the prognosis and immunotherapy response and targeted ccRCC patients’ therapy.

**KEYWORDS**
clear cell renal cell carcinoma, immunotherapy, lncRNA, prognostic signature, tumor microenvironment

1 | INTRODUCTION

Clear cell renal cell carcinoma (ccRCC), the most common pathological subtype, accounts for 70%-80% of renal cell carcinoma (RCC). Nephrectomy accounts for a primary way to treat locoregional ccRCC. Nevertheless, in 30% of patients, ccRCC eventually develops into metastasis, leading to higher mortality and systemic therapy.1

Sunitinib, the first-line targeted strategy, has been recommended for advanced ccRCC. However, sunitinib is unsatisfactory due to the emerged drug resistance. Immunotherapy, the essential antitumor treatment activating the tumor cell-killing activity of immune system, has been considered as a possible method to treat or cure certain cancers. The immune checkpoint inhibitors (ICIs) that target immune checkpoints like CTLA-4, PD-1, and PD-L1 have rapidly progressed during ccRCC treatment. Nevertheless, only a few ccRCC patients benefit from immunotherapy. Currently, there is a lack of effective biomarkers to predict immunotherapeutic response and guide therapy for ccRCC patients.

The tumor microenvironment (TME) consists of malignant cells and non-transformed cells (cells of hematopoietic origin and cells of mesenchymal origin) mixed with stromal components.2 The interaction between tumor cells and TME contributes to cancer development and influences the prognosis and response to anti-cancer therapies.3,4 Understanding the potential functional mechanism in TME might help select treatment strategies to improve the survival of ccRCC patients.5

Long noncoding RNAs (lncRNAs) have crucial roles in regulating diverse pathophysiological processes, including immune responses and cancer.6–8 LncRNA SNHG12 induces the progression and sunitinib resistance of RCC by upregulating CDC83.9 Moreover, the expression pattern of lncRNAs is associated with cancer immunity and TME.10 Tumor-infiltrating B lymphocyte-related lncRNAs indicate immune cell infiltration in the TME and potential predictive biomarkers of immunotherapy response.6 HOTAIR can modulate cellular and non-cellular components in the TME and contribute to tumor evolution and progression.11 According to our knowledge, the TME-related lncRNAs model to predict prognostic outcome and response to immune as well as targeted therapy within ccRCC is inadequate.

In the current study, a set of TME-related lncRNAs was identified, and a novel TME-related lncRNAs prognostic and treatment-related signature was constructed and applied for prognostic together with immune-related and targeted therapeutic decisions in ccRCC patients.

2 | MATERIALS AND METHODS

2.1 | Data preparation

The Series Matrix Files of GSE15641 with 32 ccRCC samples, GSE29609 with 39 ccRCC samples, GSE36895 with 29 ccRCC samples, GSE46699 with 67 ccRCC samples and GSE53757 with 72 ccRCC samples were downloaded from the gene expression omnibus (GEO). The fragments per kilobase million (FPKM) values of 539 ccRCC and 72 healthy kidney specimens from The Cancer Genome Atlas (TCGA)-kidney renal clear cell carcinoma (KIRC) were transformed into transcripts per kilobase million (TPM) values, which was considered as similar to GEO values.12 We secured 530 KIRC samples after eliminating duplicate samples. The batch effects in the TCGA and GEO datasets were corrected by the “ComBat” algorithm of the “sva” package.13 Finally, 507 ccRCC samples with overall survival (OS) of more than 30 days in TCGA-KIRC were divided into training (356 cases) and testing (151 cases) datasets with a similar clinical characteristic distribution by the R package “caret” (Table S1). There were 505 ccRCC samples with disease-free survival (DFS) information.

2.2 | ESTIMATE-based TME analysis

ESTIMATE was adopted for computing immune/stromal scores based on expression levels of specific genes.14

2.3 | Identification of TME-related LncRNAs

The differentiated genes between the high and low immune/stromal scores were elected according to the screen criteria of $|\log_2$
fold change $> 0$ and $p < 0.05$. Then, model genes closely related to immune/stromal scores were selected using the weighted gene co-expression network analysis (WGCNA). We acquired 4061 TME-related genes in the published research. A Venn diagram was used to select the intersected genes. Pearson correlation analysis with the standard as the correlation coefficient of more than 0.6 and $p < 0.05$ was adopted for identifying the potential lncRNAs related to TME-related mRNAs, and the candidate TME-related lncRNAs were used for performing further analysis.

2.4 | Gene ontology (GO) as well as kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis

GO as well as KEGG analysis was conducted to explore the fundamental mechanism of the TME-related mRNAs with R package “clusterProfiler.”

2.5 | Risk model construction and verification for KIRC

The differentiated TME-related lncRNAs between 539 ccRCC and 72 healthy kidney species in TCGA-KIRC were screened according to $|\log_{2} $ fold change $| > 1$ and $p < 0.05$. The prognostic TME-related lncRNAs in the training data were detected by univariate Cox regression. The slightly contributory TME-related lncRNAs were deleted by least absolute shrinkage and selection operator (LASSO) analysis. Finally, an optimal prognostic signature was developed using multivariate Cox regression. The risk scores were determined by risk score formula $\sum_{i=1}^{n} \exp(\text{coef}_i) $ in the training dataset (356 cases), independent testing dataset (151 patients), and the entire TCGA-KIRC cohort (507 patients). The terms $\exp(\text{coef}_i) $ represent the expression and coefficient of the gene, respectively. KIRC patients in different datasets were separately divided into low- or high-risk group according to median risk score. The separating capacity of the risk model was further verified using principal component analysis (PCA). Time-dependent receiver operating characteristic (ROC) and Kaplan–Meier (K-M) curve evaluated the risk model performance in predicting prognosis.

2.6 | Association of risk model with clinical features

In total, 248 patients with sufficient clinical characteristics including age, gender, TNM stage, T, N, and M in the entire dataset were enrolled for univariate and multivariate Cox regression. Additionally, the Wilcoxon signed-rank and chi-square tests were applied to analyze relationship between the risk score and clinical features. The K-M curve was used to detect the survival differences between both groups based on clinical characteristics-stratified subgroups.

2.7 | Construction of nomogram

The significant prognostic variables in multivariate Cox regression were applied for nomogram construction. This nomogram was later utilized for predicting outcome. Besides, calibration curves were utilized to evaluate the consistency between the predicted and actual survival results.

2.8 | Gene set enrichment analysis (GSEA) enrichment analysis

GSEA was used to reveal GO and KEGG pathways in TCGA-KIRC cases of diverse risk groups according to the gene sets “c5.go.v7.4.symbols.gmt” and “c2.cp.kegg.v7.4.symbols.gmt” using the R package “clusterProfiler.” Adjusted $p < 0.05$ stood for statistical significance.

2.9 | Immune infiltration analysis

The single-sample gene set enrichment analysis (ssGSEA) was used to quantify the different enrichment degrees of 29 immunocytes as well as immune functions of two risk groups using the R package “GSVA.” ESTIMATE algorithm was utilized to determine stromal/immune/estimated scores and tumor purity for all cases in TCGA-KIRC. In addition, differences of cytotoxic lymphocytes, CD8 T cells, neutrophils, B cells, myeloid dendritic cells, mononuclear cells, fibroblasts, and endothelial cells between two risk groups were subsequently analyzed by the Microenvironment Cell Populations (MCP) counter.

2.10 | Somatic variant analysis

Genetic mutation data of TCGA-KIRC calculated using the “Varscan” software were downloaded from the GDC, and the somatic variant landscape in the risk groups was analyzed and depicted by the R package “maftools.” TMB of all cases were counted based on the formula: (total mutation $\div$ total covered bases) $\times 10^6$.

2.11 | IPS analysis

The immunophenoscore (IPS) positively related to tumor immunogenicity was considered a better predictor for ICIs response. The IPSs of KIRC patients were obtained from The Cancer Immunome Atlas (TCIA, https://tcia.at/).
2.12 | Responses to targeted drug therapy

To evaluate the predicting value of the risk model in targeted drug sensitivity, TCGA-KIRC samples were applied to analyze the half maximal inhibitory concentration (IC50) between two risk groups by the "pRRophetic" package.25

2.13 | Statistical analysis

R software (ver. 4.1.2) was employed for statistical analysis. Wilcoxon's signed-rank test or Student's t test was utilized to compare differences between the two groups. For the variable comparison in more than two groups, either the Kruskal–Wallis test or one-way ANOVA was employed. The chi-square test was performed to analyze the frequency differences. The survival discrepancies were evaluated using the log-rank test. The differences were regarded as significant when the bilateral p-value was <0.05.

3 | RESULTS

3.1 | Identification of TME-related IncRNAs

The immune/stromal components were quantitatively analyzed by ESTIMATE-derived immune/stromal scores based on transcriptomic RNA-seq data from 769 KIRC specimens derived from TCGA and GEO. The scope of immune scores was between −963.55 and 3632.46, whereas that of stromal scores was between −1390.33 and 2247.83 (Table S2). In the next step, these samples were classified into two clusters according to the median value. Under thresholds of |log2 fold change| > 0 and p-value < 0.05, the DEGs amounted to 5524 for high vs low immune scores and to 6039 DEGs for high vs. low stromal scores (Figure 1A-D). The primary modules relevant to these immune/stromal scores were further identified using WGCNA. According to module trait heatmap, green model that contained 708 genes together with purple module that contained 269 genes showed higher relevance to immune and stromal scores, respectively (Figure 1E,F; R² = 0.86 and p = 5e−219 in the green module, R² = 0.72 and p = 1e−120 in the purple model). We obtained 4061 TME-related genes from a previous study.16 Finally, 439 genes were screened out by intersection analysis (Figure 1G; Table S3). GO enrichment assessment revealed that the TME-associated genes were closely associated with T-cell activation, regulation of T-cell activation, positive regulation of cytokine production, leukocyte cell–cell adhesion, and regulation of leukocyte cell–cell adhesion (Figure 1H).

KEGG enrichment evaluation verified that these genes were related with the hematopoietic cell lineage, cytokine–cytokine receptor interaction, type I diabetes mellitus, allograft rejection, and viral protein interaction with cytokine and cytokine receptor (Figure 1I). Results suggested that these genes could be TME-related genes. Finally, 364 TME-related IncRNAs were selected with a threshold coefficient of correlation >0.6 and p < 0.05 (Table S4).

3.2 | Establishment of a risk model

Under thresholds of |log2 fold change| > 1 and p-value < 0.05, we screened out 232 significantly and differentially expressed IncRNAs associated with TME for 539 ccRCC vs 72 healthy kidney specimens from TCGA-KIRC (Figure 2A,B). The prognostic signature was constructed in the training dataset. 127 TME-related IncRNAs were closely related with OS by univariate Cox regression (Table S5). 14 TME-related IncRNAs screened by LASSO Cox regression analysis were further applied for multivariate Cox regression analysis (Figures 2C). Finally, a risk model was constructed based on six TME-related IncRNAs to assess its value in predicting the prognosis of ccRCC patients. The univariate and multivariate Cox regression analyses suggested that the six TME-associated IncRNAs were closely associated with OS except for AC084876.1 (Figures 2E,F).

3.3 | Validating the performance of the risk model

Depending on the median risk score of 0.926, the samples in the training dataset were separated into low- and high-risk groups. PCA analysis showed that the signature had good performance in clustering (Figure 3A). The distribution of the risk score and survival status of the six TME-related IncRNAs between two risk groups in the training dataset are shown in Figures 3B,C. Clearly, the high-risk group contained more death samples. According to K–M plots, patients in low-risk group showed better OS and DFS than those in high-risk group (p < 0.001, Figure 3D,E). Additionally, the 1-, 3-, 5-year AUCs of the risk model were 0.738, 0.668, and 0.757, separately (Figure 3F). Furthermore, the prognostic model in the testing dataset and the entire dataset were also tested. Similarly, the low-risk group showed a better clinical outcome than the high-risk group in the testing dataset (Figure 3G,H) and entire dataset (Figure 3I,J), respectively. The AUCs of 1, 3, and 5 years were 0.631, 0.724, and 0.736 in the testing dataset and 0.704, 0.683, and 0.750 in the entire dataset (Figure 3K,L). Additionally, the expression levels of the AC008870.2, AC068792.1, LINC01094, LINC00460, and AC084876.1 in the TCGA-KIRC were upregulated in the ccRCC samples, whereas the AC007637.1 was downregulated (Figure S1).

3.4 | Relationships between the risk model and clinical characteristics

The risk score and clinical features were analyzed using univariate and multivariate Cox regression over the whole TCGA-KIRC dataset, revealing that our risk model independently predicted ccRCC...
prognosis (Figures 4A,B). In the clinical heatmap, tight correlations of grade, T, and stage with the risk model by the \( \chi^2 \) test were observed (Figure 4C). As revealed by scatter diagrams, stage, grade, and T had high-risk scores based on Wilcoxon’s signed-rank results (Figures 4D-F). The OS stratified by the clinical subgroups varied prominently between two risk groups, except N1 (Figure S2). To test the clinical practicability of the TME-related lncRNAs signature, the two independent prognostic indicators yielded by the multivariable Cox analyses, the risk score and age, were incorporated to develop a nomogram for the prognostic prediction. Patients were assigned a total point based on each prognostic parameter in the nomogram (Figure 4G). Higher total points presented a worse outcome. Calibration curves indicated that the nomogram exhibited a similar performance in predicting prognostic probability to an ideal model (Figures 4H).

3.5 | GSEA analysis

The underlying mechanism between the two risk groups was interpreted using the GSEA. According to GO assessment results, enrichment of “activation of immune response,” “adaptive immune response based on somatic recombination of immune receptor built from immunoglobulin superfamily domains,” “antigen receptor mediated signaling pathway,” “B cell activation,” and “B cell mediated immunity” was observed in the high-risk group (Figures 5A,B). Additionally, KEGG results revealed a high pathway enrichment, such as “autoimmune thyroid disease,” “chemokine signaling pathway,” “cytokine-cytokine receptor interaction,” “primary immunodeficiency,” and “type I diabetes mellitus,” in the high-risk group (Figures 5C, D).
3.6 | Relationship between immune cell infiltration and the risk model

As shown in the GSEA results, a tight linkage of the risk model to the immunity was observed. To confirm the above-mentioned conclusion, 29 immunocytes plus immunity functions were systematically evaluated through ssGSEA utilizing the TCGA-KIRC cohort. A heatmap revealed the immune infiltration landscape (Figure 6A). The high-risk patients scored prominently higher for ten immunocytes (e.g., activated dendritic cells, macrophages, CD8\(^+\) T cells, TILs, and T-helper cells), whereas the low-risk patients scored higher for mast cells (Figure 6F). In addition, the high-risk patients scored higher for immunity functions, such as APC co-activation or co-repression, CCR chemotaxis, immunochekpoints, Type I INF reaction, HLA (human leukocyte antigen), inflammation promotion, MHC class I, parainflammation, and T cell co-activation or co-repression. Low-risk patients scored high for the Type II INF reaction (Figure 6G). In contrast, the high-risk patients scored prominently higher ESTIMATE-derived stromal/immune/estimate scores and lower tumor purity scores than the low-risk patients (Figures 6B-E). MCF counter was utilized for quantifying the cytotoxic lymphocytes, CD8\(^+\) T cells, mononuclear cells, neutrophils, B cells, myeloid dendritic cells, endothelialcytes, and fibroblasts. The CD8\(^+\) T cells, cytotoxic lymphocytes, B cells, and mononuclear cells had positively associated with the risk score, whereas neutrophils and endothelial cells exhibited negative association with the risk score (Figure 6H). Moreover, the high-risk patients demonstrated higher numbers of B cells, cytotoxic lymphocytes, CD8\(^+\) T cells, and mononuclear cells, whereas the low-risk patients exhibited higher neutrophil and endothelialcyte counts (Figure 6I-N).

3.7 | Correlations between somatic mutation and risk model

The Varscan mutation annotation files of the TCGA-KIRC cohort were used to analyze the total TMB and mutation distribution in two risk groups. The patients with TMB and somatic mutation information were assigned into high- and low-risk groups. The TMB values were significantly higher in high-risk group than those in low-risk group and positively related with the risk scores (Figures 7A,B). Next, these samples were assigned into the H-TMB group and the L-TMB group using the median TMB. According to the Kaplan–Meier plot, the OS was inferior among the H-TMB population (Figure 7C). Further, combination of TMB and the risk model had excellent risk stratification (\(p<0.001\), Figure 7D). Moreover, the somatic mutation counts in high-risk group were significantly higher than those in low-risk group and positively related to the risk scores (Figures 7E,F). The waterfall plot implied the differences in mutation landscapes and the frequency of the first 20 mutated genes between two risk groups (Figures 7J-I). VHL (Von Hippel–Lindau Tumor Suppressor), PBRM1 (Polybromo 1), and TTN (Titin) had more than 10% mutation rate in both risk groups. The mutation rate of BAP1 was 15% and 5% among the high- and low-risk populations, respectively (\(p = 0.004\), Figure 7K). Patients with BAP1 mutation had significantly shorter OS than those with BAP1 wild (\(p < 0.001\), Figure 7G). The risk model combined with BAP1 mutation status had excellent risk stratification (\(p < 0.001\), Figure 7H).
The risk model for ICIs as well as targeted therapeutic responses

To validate whether higher TMB among high-risk group implied superior outcomes with ICIs, we evaluated IPS, IPS-CTLA4 (Cytotoxic T lymphocyte antigen-4), IPS-PD-1, and IPS-PD-1+CTLA4 to unravel the response to ICIs therapy in KIRC patients. The high IPS-PD-1+CTLA4 scores among the high-risk population suggested that the patients were better responders to ICIs (p = 0.0082, Figure 8A-D). In addition, immune checkpoints correlated with an individual's response to cancer immunotherapy. The risk scores positively correlated with the PD-1, LAG3, PD-L1, TIGIT, and CTLA-4...
levels (Figure 8E). Besides, the high-risk group also exhibited higher PD-1, LAG3, TIGIT, CTLA-4, and IDO1 levels (Figure 8F). The association of risk model with the anti-ccRCC targeted drug sensitivity were analyzed. High-risk population showed lower IC50s of anti-tumour drugs, like sunitinib ($p = 1.7e-09$, Figure 8H), rapamycin ($p = 4.7e-08$, Figure 8G), and temsirolimus ($p = 4.3e-12$, Figure 8L). The above results demonstrated that our constructed risk model could predict the sensitivity to anti-ccRCC ICIs and targeted therapeutics.

4 | DISCUSSION

The TME includes tumor cells and surrounding nontumor components, providing an optimum environment for tumor cell development. Research reveals that the immunosuppressive TME helps in tumor cell evasion from immunity and influences the therapeutic effect of antitumor drugs. Despite the immunogenicity of ccRCC, various TKI and ICI resistances are elicited using the exceptionally dynamic, heterogeneous, and adaptive TME. Like other immunogenic carcinomas, the total immune infiltration and tumor mutation load can serve as therapeutic response predictors, but their significance in clinical decision settings is unclear. The prognostic biomarker recognition for TME is probably conducive to define the potential checkpoint blockade responders and discovering novel therapeutic targets.

The study has demonstrated a crucial function exerted by IncRNAs in the TME on multiple tumor-related processes. Many IncRNAs have critical role in regulating T-cell function and immune response. Some stromal IncRNAs regulate cancer-associated fibroblast (CAF) metabolism, enhancing the metastasis of tumor cells. LncRNAs can be considered as tumor biomarkers due to their dysregulation during the development and progression of cancer. Another study established that a TME-related gene signature might help develop personalized immunotherapy. However, the TME-associated IncRNAs prognostic signatures for the outcome and immunotherapeutic response forecasting among patients with ccRCC have been explored scarcely.

In the current study, the fused mRNA expression data were exploited to derive the immune/stromal scores using the ESTIMATE algorithm. We filtered TME-associated mRNAs based on immune/stromal score disparities combined with the WGCNA result. As revealed by the GO enrichment assessment, these TME-associated genes were linked tightly to the activation of T cell and regulation, positive regulation of cytokine generation, and leukocyte intercellular adhesion and regulation. The KEGG results identified enrichment of these genes in the hematopoietic cell lineage and the interplay between cytokine and cytokine receptors. Subsequently, 364 TME-related IncRNAs were selected with the threshold of correlation coefficient $>0.6$ and $p < 0.05$. Based on the TME-associated IncRNAs,
we then developed a prognostic signature by exploiting the training dataset. Compared with the high-risk population, the OS and DFS were superior among the low-risk population. A similar conclusion was obtained in the test and entire datasets. Univariate and multivariate Cox regression analysis suggested that the risk score and age were individual outcome predictors for the survival from KIRC. The nomogram, including age and risk score, signified an excellent clinical application value in estimating ccRCC survival.

Among the six TME-related lncRNAs, the expression levels of AC008870.2, AC068792.1, LINC01094, LINC00460, and AC084876.1 were upregulated in the ccRCC samples and that of AC007637.1. LINC01094 facilitates ccRCC cell growth, metastasis, and radio resistance by the ceRNA mechanism.\(^{34,35}\) LINC01094 enhances ccRCC cell growth, invasion and migration through down-regulating miR-184 and upregulating SLC2A3.\(^{36}\) High LINC01094 expression predicts dismal survival for gastric cancer (GC) cases with infiltration of macrophages.\(^{37}\) Studies have demonstrated that LINC00460 could affect cell proliferation, invasion, and migration in GC, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC).\(^{38–41}\) LINC00460 upregulation is related to clinical stage and inferior OS in ccRCC patients and accelerated cell proliferation, migration, and invasion through the ceRNA mechanism.\(^{42}\) The study combined with present studies has demonstrated that LINC01094 and LINC00460 might be oncogenic lncRNAs in ccRCC. No research is present about the AC008870.2, AC068792.1, AC007637.1, and AC084876.1 in ccRCC. So, further study must be performed to probe their functions in ccRCC.

Additionally, molecular mechanism between two risk models was further analyzed. GSEA-based GO annotation indicated that the high-risk group exhibited more “activation of immune response,” “adaptive immune response based on somatic recombination of immune receptor developed from immunoglobulin superfamily domains,” “antigen receptor-mediated signalling pathway,” “B cell activation,” and “B cell-mediated immunity.” According to KEGG analysis, the “autoimmune thyroid disease,” “chemokine signalling pathway,” “cytokine- cytokine receptor interaction,” “primary immunodeficiency,”

FIGURE 5 Gene set enrichment analyses between the high- and low-risk groups. GO enrichment analyses in the high-risk group (A) and the low-risk group (B). KEGG pathway analyses in the high-risk group (C) and the low-risk group (D)
and "type I diabetes mellitus" were enriched in the high-risk group. Therefore, TME-related IncRNAs might influence the development and immune response in ccRCC via these immune pathways.

Using our risk model, a difference in infiltration of immunocyte was observed between two risk groups. The higher immune score for high-risk patients might contribute to dismal survival. This observation was consistent with the former research that demonstrated that patients with high immune scores have poorer OS than those with low immune scores. CcRCC, as an immunogenic tumor, induces immune dysfunction by infiltrating immunosuppressive cells in TME. In our study, the infiltrations of six immunocyte types markedly increased in high-risk group. Such conclusion is similar to
FIGURE 7  Somatic mutational analyses between high- and low-risk groups. (A) Difference in TMB between the high- and low-risk groups. (B) Correlation between TMB and risk scores. (C) Survival analysis of OS between H- and L-TMB groups. (D) Survival analysis of OS stratified by TMB and risk groups. (E) Difference in somatic mutation counts between the high- and low-risk groups. (F) Correlation between somatic mutation counts and risk scores. (G) Survival analysis of OS between BAP1 mutation and wild groups. (H) Survival analysis of OS stratified by BAP1 mutation status and risk groups. The top 20 frequently mutated genes in the high-risk group (I) and low-risk group (J). (K) Proportion of BAP1 mutation status in high- and low-risk groups. (L) Correlation between the risk score and common immune checkpoints. (M) Expression levels of the common immune checkpoints between the high- and low-risk groups. ***p < 0.001; *p < 0.05; ns: no significance
the study, which has demonstrated that high-risk glioma cases with increased infiltration of immunocytes presented a poor prognosis.

The large amount of CD8+ T cells and cytotoxic T lymphocytes infiltration in the ccRCC TME cannot prolong survival due to immune evasion via T cell exhaustion. CC motif chemokine receptors (CCR) and dendritic cells were high in the high-risk group. The CCL/CCR axis has pro-cancer properties in proliferation, migration, invasion, and angiogenesis. It can also recruit dendritic cells to increase the anti-cancer response.

In conclusion, the obtained results indicate that our constructed prognostic signature may have the ability to predict prognosis and infiltration of immune cells in ccRCC patients with clinical application value.

Currently, several KIRC clinical trials are in progress to estimate the efficacy of ICIs. The value of PD-L1 for predicting response to ICIs in ccRCC is controversial. TMB as a biomarker for predicting the efficacy of ICIs in ccRCC need further investigation. In the present study, the high-risk cases showed increased TMB compared with low-risk counterparts. BAP1 mutation in 10%-20% of ccRCC exerted a crucial function on genome stability. The high-risk population displayed the prominently increased BAP1 mutation rate compared with low-risk population. Additionally, BAP1 mutation contributed to poor survival among patients with ccRCC, in agreement with the prior work. Incorporating BAP1 mutation could improve the abilities of our signature in risk stratification. The IPS-PD-1+CTLA4 score was remarkably increased among the high-risk group. The risk score was positively associated with the PD-1, PD-L1, LAG3, TGIT, and CTLA4 levels. The high-risk population exhibited higher PD-1, LAG3, CTLA-4, IDO1, and TGIT levels. These immune checkpoints directly inhibit the effector of T-cell function and are responsible for exhausted T cells. Thus, the high-risk patients might have superior benefits from immunotherapy. Additionally, the IC50s of rapamycin, temsirolimus and sunitinib decreased in high-risk population, which signifies that these patients showed higher drug sensitivity. Taken together, our constructed risk model helped to predict the sensitivity to targeted therapeutics and immunotherapy in ccRCC patients.

Certain limitations should be noted. Firstly, the retrospective study and data bias on algorithm may influence the conclusion reliability. So, the prospective and multicentre trials are required to demonstrate the clinical availability. Secondly, further study is required to reveal the molecular mechanisms of the six IncRNAs in tumorigenesis and the development of ccRCC. Thirdly, the study of the

**FIGURE 8** Response to immunotherapy and sensitivity to targeted therapy between the high- and low-risk groups. (A-D) The association between IPS and the risk signature of KIRC patients. (E) Correlation between the risk score and common immune checkpoints. (F) Expression levels of the common immune checkpoints between the high- and low-risk groups. IC50 values between the high- and low-risk groups for axitinib (G), sunitinib (H), sorafenib (I), rapamycin (G), pazopanib (K), and emsirolimus (L). ***p < 0.001; *p < 0.05; ns: no significance.
synergistic effect of cell and spatial domains in antitumoral immunity processes was not mentioned.

In summary, the 6 TME-related lncRNAs-based risk model reliably predicted sensitivity to targeted therapeutics and immunotherapy among ccRCC cases.

AUTHOR CONTRIBUTIONS
L Zhou was responsible for study conception and design, data acquisition, data analysis, and drafting and revision of the article. H Fang was responsible for data analysis and drafting. G Fei was accountable for the study guide. M Yin and H Long were responsible for data acquisition and article revision. G Weng was responsible for the revision of the article.

ACKNOWLEDGMENT
We would like to thank TCGA, PubMed project organizers, shengxinzuixuewang, and "AIM" workshop.

CONFLICT OF INTEREST
The authors declared no conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Libin Zhou https://orcid.org/0000-0002-8929-4214

REFERENCES
1. Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7(1):354.
2. Butturini E, Carcereri de Prati A, Boriero D, Mariotto S. Tumor dormancy and interplay with hypoxic tumor microenvironment. Int J Mol Sci. 2019;20(17):4305.
3. Netea-Maier RT, Smit JWA, Netea MG. Metabolic changes in tumor cells and tumor-associated macrophages: a mutual relationship. Cancer Lett. 2018;413:102-109.
4. Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumor growth and metastasis. Nat Rev Cancer. 2019;19(1):9-31.
5. Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes A. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.
6. Zhou M, Zhang Z, Bao S, et al. Computational recognition of INcRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2021;22(3):bbaa047.
7. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96-118.
8. Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18(9):962-972.
9. Liu Y, Cheng G, Huang Z, et al. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death Dis. 2020;11(7):515.
10. Wang L, Felts SJ, Van Keulen VP, et al. Integrative genome-wide analysis of Long noncoding RNAs in diverse immune cell types of melanoma patients. Cancer Res. 2018;78(15):4411-4423.
11. Botti G, Scognamiglio G, Aquino G, Ligori G, Cantile M. LncRNA HOTAIR in tumor microenvironment: what role? Int J Mol Sci. 2019;20(9):2279.
12. Wagner GP, Kin K, Lynch VJ. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci. 2012;131(4):281-285.
13. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-127.
14. Yoshihara K, Shahrparad A, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
15. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17.
16. Zheng M, Long J, Chelariu-Raicu A, et al. Identification of a novel tumor microenvironment prognostic signature for advanced-stage serous ovarian cancer. Cancers (Basel). 2021;13(13):3343.
17. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284-287.
18. Zhang Z, Kattan MW. Drawing nomograms with R: applications to categorical outcome and survival data. Ann Transl Med. 2017;5(10):211.
19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
20. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
21. Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.
22. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffer HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747-1756.
23. Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297-303.
24. Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248-262.
25. Goelepe HR, Cox N, Huang RS. pRRhoetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9(9):e107468.
26. Lai Y, Tang F, Huang Y, et al. The tumor microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. J Cell Physiol. 2021;236(3):1616-1627.
27. Sheng X, Parmentier JH, Tucci J, et al. Adipocytes sequester and metabolize the chemotherapeutic daunorubicin. Mol Cancer Res. 2017;15(12):1704-1713.
28. Obradovic A, Chowdhury N, Haake SM, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021;184(11):2988-3005.e2916.
29. Giraldo NA, Becht E, Vano Y, et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23(15):4416-4428.
30. Lin YH, Wu MH, Yeh CT, Lin KH. Long non-coding RNAs as mediators of tumor microenvironment and liver cancer cell communication. Int J Mol Sci. 2018;19(12):3742.
31. Zhao L, Ji G, Le X, et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res. 2017;77(6):1369-1382.
32. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965-3981.
33. Zhang L, Li J, Zhang M, et al. Identification of a six-prognostic gene signature characterized by tumor microenvironment immune profiles in clear cell renal cell carcinoma. Front Genet. 2021;12:722421.
34. Jiang Y, Li W, Yan Y, Yao X, Gu W, Zhang H. LINC01094 triggers radio-resistance in clear cell renal cell carcinoma via miR-577/CHEK2/FOXM1 axis. Cancer Cell Int. 2020;20:274.
35. Jiang Y, Zhang H, Li W, Yan Y, Yao X, Gu W. FOXM1-activated LINC01094 promotes clear cell renal cell carcinoma development via MicroRNA 224-5p/CHSY1. Mol Cell Biol. 2020;40(3):e00357-19.
36. Xu H, Wang X, Wu J, et al. Long non-coding RNA LINC01094 promotes the development of clear cell renal cell carcinoma by upregulating SLC2A3 via MicroRNA-184. Front Genet. 2020;11:562967.
37. Ye Y, Ge O, Zang C, Yu L, Eucker J, Chen Y. LINC01094 predicts poor prognosis in patients with gastric cancer and is correlated with EMT and macrophase infiltration. Technol Cancer Res Treat. 2022;21:15330338221080977.
38. Zhang S, Xu J, Wang H, Guo H. Downregulation of long noncoding RNA LINC00460 expression suppresses tumor growth in vitro and in vivo in gastric cancer. Cancer Biomark. 2019;24(4):429-437.
39. Yuan B, Yang J, Gu H, Ma C. Down-regulation of LINC00460 represses metastasis of colorectal cancer via WWC2. Dig Dis Sci. 2020;65(2):442-456.
40. Hou P, Meng S, Li M, et al. LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification. J Exp Clin Cancer Res. 2021;40(1):52.
41. Jiang Y, Cao W, Wu K, et al. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus. J Exp Clin Cancer Res. 2019;38(1):365.
42. Zhang S, Zhang F, Niu Y, Yu S. Aberration of IncRNA LINC00460 is a promising prognosis factor and associated with progression of clear cell renal cell carcinoma. Cancer Manag Res. 2021;13:6489-6497.
43. Zeng D, Zhou R, Yu Y, et al. Gene expression profiles for a prognostic immunoscore in gastric cancer. Br J Surg. 2018;105(10):1338-1348.
44. Díaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16(12):721-735.
45. Yin W, Jiang X, Tan J, et al. Development and validation of a tumor mutation burden-related immune prognostic model for lower-grade glioma. Front Oncol. 2020;10:1409.
46. Senbabaoglu Y, Gejman RS, Winer AG, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17(1):231.
47. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550-1567.
48. Korbecki J, Grochans S, Gutowska I, et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. Int J Mol Sci. 2020;21(20):7619.
49. Mori K, Abufaraj M, Mostafaei H, et al. The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2021;79(6):783-792.
50. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813.
51. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421.
52. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751-759.
53. Joseph RW, Kapur P, Serie DJ, et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer. 2014;120(7):1059-1067.
54. Blank CU, Haining WN, Held W, et al. Defining 'T cell exhaustion'. Nat Rev Immunol. 2019;19(11):665-674.
55. O’Connell P, Hyslop S, Blake MK, et al. SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment. J Immunol. 2021;206(1):193-205.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.